SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector
- Leverage SBI's robust lentivector expression technology to study the SARS-CoV-2 nucleocapsid protein
- Choose ready-to-package plasmid or ready-to-transduce virus
- Additional SARS-CoV-2 expression constructs also available
Products
| Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
|---|---|---|---|---|---|---|---|---|
| CVD19-120PA-1 | SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro Plasmid | 10 µg | $755 |
|
||||
| CVD19-120VA-1 | SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro Pre-packaged Lentivirus | >2 x 10^6 IFUs | $755 |
|
||||
Overview
Overview
Advance your COVID-19 studies with SBISBI is helping scientists around the globe respond to the ongoing COVID-19 pandemic with research tools that get your studies up and running quickly and efficiently. Our SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector is based on our robust pCDH-CMV-MCS-EF1α-Puro Cloning and Expression Lentivector (Cat.# CD510B-1/VA-1), and delivers SARS-CoV-2 N protein expression from the CMV promoter with a separate EF1α promoter driving the expression of the puromycin resistance gene for selection. Available in both plasmid and pre-packaged lentivirus formats, the SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector enables a wide range of studies using the systems of your choice.
- Leverage SBI's robust lentivector expression technology to study the SARS-CoV-2 nucleocapsid protein
- Choose ready-to-package plasmid or ready-to-transduce virus
- Additional SARS-CoV-2 expression constructs also available
See all of our COVID-19-related Expression Constructs
| Catalog Number | Product name |
|---|---|
| CVD19-100PA/VA-1 | ACE2 Expression Lentivector, pCDH-CMV-ACE2-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-140PA/VA-1 | NRP1 Expression Lentivector, pCDH-CMV-NRP1-EF1α-Neo (Plasmid or Pre-packaged Lentivirus) |
| CVD19-120PA/VA-1 | SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-130PA/VA-1 | SARS-CoV-2 Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-135PA/VA-1 | SARS-CoV-2 Humanized Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-hS-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-200A-1 | HEK293 ACE2 Stable Cell Line |
| CVD19-260A-1 | HEK293-ACE2-NRP1 Overexpression Stable Cell Line |
| CVD19-220A-1 | HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line |
| CVD19-420A-1 CVD19-425A-1 | "N" SARS-CoV-2 Nucleocapsid mRNA |
| CVD19-430A-1 CVD19-435A-1 | "S" SARS-CoV-2 Spike Glycoprotein mRNA |
| CVD19-440A-1 CVD19-445A-1 | "S" SARS-CoV-2 Spike Omicron mRNA |
References
How It Works
Supporting Data
FAQs
Resources
Citations
Related Products
Products
| Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
|---|---|---|---|---|---|---|---|---|
| CVD19-120PA-1 | SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro Plasmid | 10 µg | $755 |
|
||||
| CVD19-120VA-1 | SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro Pre-packaged Lentivirus | >2 x 10^6 IFUs | $755 |
|
||||
Overview
Overview
Advance your COVID-19 studies with SBISBI is helping scientists around the globe respond to the ongoing COVID-19 pandemic with research tools that get your studies up and running quickly and efficiently. Our SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector is based on our robust pCDH-CMV-MCS-EF1α-Puro Cloning and Expression Lentivector (Cat.# CD510B-1/VA-1), and delivers SARS-CoV-2 N protein expression from the CMV promoter with a separate EF1α promoter driving the expression of the puromycin resistance gene for selection. Available in both plasmid and pre-packaged lentivirus formats, the SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector enables a wide range of studies using the systems of your choice.
- Leverage SBI's robust lentivector expression technology to study the SARS-CoV-2 nucleocapsid protein
- Choose ready-to-package plasmid or ready-to-transduce virus
- Additional SARS-CoV-2 expression constructs also available
See all of our COVID-19-related Expression Constructs
| Catalog Number | Product name |
|---|---|
| CVD19-100PA/VA-1 | ACE2 Expression Lentivector, pCDH-CMV-ACE2-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-140PA/VA-1 | NRP1 Expression Lentivector, pCDH-CMV-NRP1-EF1α-Neo (Plasmid or Pre-packaged Lentivirus) |
| CVD19-120PA/VA-1 | SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-130PA/VA-1 | SARS-CoV-2 Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-135PA/VA-1 | SARS-CoV-2 Humanized Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-hS-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-200A-1 | HEK293 ACE2 Stable Cell Line |
| CVD19-260A-1 | HEK293-ACE2-NRP1 Overexpression Stable Cell Line |
| CVD19-220A-1 | HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line |
| CVD19-420A-1 CVD19-425A-1 | "N" SARS-CoV-2 Nucleocapsid mRNA |
| CVD19-430A-1 CVD19-435A-1 | "S" SARS-CoV-2 Spike Glycoprotein mRNA |
| CVD19-440A-1 CVD19-445A-1 | "S" SARS-CoV-2 Spike Omicron mRNA |